Compare, Analyse Glenmark Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
TEVA PHARMA
Dec-13
GLENMARK PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs5733,102-   
Low Rs1952,695-   
Sales per share (Unadj.) Rs387.81,780.3-  
Earnings per share (Unadj.) Rs34.4111.2-  
Cash flow per share (Unadj.) Rs50.1255.1-  
Dividends per share (Unadj.) Rs2.5097.36-  
Avg Dividend yield %0.73.4 19.4%  
Book value per share (Unadj.) Rs249.61,977.6-  
Shares outstanding (eoy) m282.17848.00-   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.01.6 60.8%   
Avg P/E ratio x11.226.1 42.9%  
P/CF ratio (eoy) x7.711.4 67.5%  
Price / Book Value ratio x1.51.5 105.0%  
Dividend payout %7.387.5 8.3%   
Avg Mkt Cap Rs m108,3532,457,911 4.4%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m23,4370-   
Avg. sales/employee Rs ThNM33,590.8-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,098.4-  
INCOME DATA
Net Sales Rs m109,4391,509,736 7.2%  
Other income Rs m5020-   
Total revenues Rs m109,9411,509,736 7.3%   
Gross profit Rs m21,289413,442 5.1%  
Depreciation Rs m4,436122,033 3.6%   
Interest Rs m3,53129,654 11.9%   
Profit before tax Rs m13,825261,755 5.3%   
Minority Interest Rs m01,189 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-171,828 0.0%   
Tax Rs m4,124-3,196 -129.0%   
Profit after tax Rs m9,70194,312 10.3%  
Gross profit margin %19.527.4 71.0%  
Effective tax rate %29.8-1.2 -2,443.3%   
Net profit margin %8.96.2 141.9%  
BALANCE SHEET DATA
Current assets Rs m73,5961,019,670 7.2%   
Current liabilities Rs m42,010889,239 4.7%   
Net working cap to sales %28.98.6 334.1%  
Current ratio x1.81.1 152.8%  
Inventory Days Days791 7.3%  
Debtors Days Days8696 89.4%  
Net fixed assets Rs m67,093493,113 13.6%   
Share capital Rs m2823,716 7.6%   
"Free" reserves Rs m70,1480-   
Net worth Rs m70,4301,677,031 4.2%   
Long term debt Rs m38,888771,962 5.0%   
Total assets Rs m140,6893,450,232 4.1%  
Interest coverage x4.99.8 50.0%   
Debt to equity ratio x0.60.5 120.0%  
Sales to assets ratio x0.80.4 177.8%   
Return on assets %9.43.6 261.8%  
Return on equity %13.85.6 244.9%  
Return on capital %15.94.9 321.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m23,7290-   
CASH FLOW
From Operations Rs m11,312240,574 4.7%  
From Investments Rs m-6,752-85,245 7.9%  
From Financial Activity Rs m-4,418-288,585 1.5%  
Net Cashflow Rs m278-133,256 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 74.32 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare GLENMARK PHARMA With: SOURCE NATURAL FOODS  ALBERT DAVID  SUVEN PHARMACEUTICALS  BACIL PHARMA  FREDUN PHARMA  



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views On News

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

More
-->

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2022
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: How to Profit from Sensex 100,000
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

GLENMARK PHARMA SHARE PRICE


Jan 21, 2022 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS